Lowering development costs
We’re taking a scalpel to biologic development costs by using advanced analytics to demonstrate analytical resemblance between biosimilars candidates and reference biologics.
It’s an innovative approach we’re using to reduce the scope and cost of human clinical trials – which can significantly
lower the cost of drug development.
